Compare Clorox Co (CLX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Clorox Co vs Revvity Inc — how do they compare? Clorox Co trades at $95.56 (market cap $11.46B), while Revvity Inc trades at $111.4 (market cap $12.41B). The key difference: Clorox Co and Revvity Inc are close in size by market cap, and Clorox Co pays the higher dividend (5.23%). Which is the better fit depends on your goals.
| CLX | RVTY | |
|---|---|---|
Market Cap | $11.46B | $12.41B |
Sector | Consumer Staples | Technology |
52-Week High | $131.43 | $117.75 |
52-Week Low | $86.12 | $82.26 |
Enterprise Value | $14.76B | $14.90B |
Dividend Yield | 5.23% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLX trades at $95.05, down 1.56% on the day, with technical indicators showing a bearish trend. The company reported strong Q1 2026 earnings beat with EPS of $1.64 versus $1.55 expected, though revenue trends remain flat. Recent corporate developments include a simplified operating structure announcement and CEO transition for health reasons. The stock offers a 5%+ dividend yield with recent H1-26 dividend of $1.24 payable May 2026.
CLX presents a mixed outlook with attractive dividend income but faces growth challenges. The 8.7% upside to consensus price target of $103.38 suggests moderate potential, though high P/B ratio of 41.4 and declining revenue projections for 2026 warrant caution. Key risks include execution of new operating structure and competitive pressures in consumer staples.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
